New York State Common Retirement Fund Purchases 972 Shares of Merit Medical Systems, Inc. (NASDAQ:MMSI)

New York State Common Retirement Fund raised its holdings in Merit Medical Systems, Inc. (NASDAQ:MMSI) by 0.6% during the 4th quarter, HoldingsChannel.com reports. The fund owned 168,367 shares of the medical instruments supplier’s stock after buying an additional 972 shares during the period. New York State Common Retirement Fund’s holdings in Merit Medical Systems were worth $16,284,000 at the end of the most recent quarter.

Other institutional investors also recently added to or reduced their stakes in the company. Farther Finance Advisors LLC raised its stake in Merit Medical Systems by 32.7% in the third quarter. Farther Finance Advisors LLC now owns 1,056 shares of the medical instruments supplier’s stock worth $104,000 after buying an additional 260 shares in the last quarter. Harvest Fund Management Co. Ltd purchased a new position in shares of Merit Medical Systems in the third quarter worth about $120,000. GAMMA Investing LLC raised its position in Merit Medical Systems by 14.7% during the 4th quarter. GAMMA Investing LLC now owns 1,494 shares of the medical instruments supplier’s stock worth $144,000 after buying an additional 191 shares during the last quarter. TD Private Client Wealth LLC boosted its holdings in Merit Medical Systems by 13.9% in the third quarter. TD Private Client Wealth LLC now owns 1,732 shares of the medical instruments supplier’s stock valued at $171,000 after purchasing an additional 211 shares during the last quarter. Finally, Sanctuary Advisors LLC purchased a new stake in shares of Merit Medical Systems in the third quarter worth about $207,000. Hedge funds and other institutional investors own 99.66% of the company’s stock.

Analyst Ratings Changes

Several research firms recently commented on MMSI. Robert W. Baird raised their price target on shares of Merit Medical Systems from $107.00 to $109.00 and gave the company an “outperform” rating in a research report on Thursday, October 31st. Piper Sandler reissued an “overweight” rating and issued a $116.00 price objective (up from $114.00) on shares of Merit Medical Systems in a research note on Wednesday, January 29th. Needham & Company LLC raised their target price on shares of Merit Medical Systems from $109.00 to $122.00 and gave the stock a “buy” rating in a research note on Wednesday, January 29th. Barrington Research upped their price objective on shares of Merit Medical Systems from $114.00 to $115.00 and gave the company an “outperform” rating in a report on Wednesday, January 29th. Finally, Wells Fargo & Company raised Merit Medical Systems from an “equal weight” rating to an “overweight” rating and raised their target price for the stock from $103.00 to $120.00 in a research note on Wednesday, December 11th. Two equities research analysts have rated the stock with a hold rating, nine have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Merit Medical Systems presently has an average rating of “Moderate Buy” and an average target price of $109.80.

Merit Medical Systems Stock Down 2.4 %

Merit Medical Systems stock opened at $103.16 on Monday. The stock’s fifty day simple moving average is $102.64 and its 200-day simple moving average is $99.64. The company has a current ratio of 5.36, a quick ratio of 3.82 and a debt-to-equity ratio of 0.57. Merit Medical Systems, Inc. has a twelve month low of $70.70 and a twelve month high of $111.45. The firm has a market capitalization of $6.01 billion, a P/E ratio of 50.57, a P/E/G ratio of 2.34 and a beta of 0.87.

Merit Medical Systems Company Profile

Merit Medical Systems, Inc designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States and internationally. It operates in two segments, Cardiovascular and Endoscopy. The company provides micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention, including angiography, drainage, delivery systems, and embolotherapy products; spine products, such as vertebral augmentation, radiofrequency ablation, and bone biopsy systems; oncology products; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions.